Results 31 to 40 of about 31,486 (223)

National Institute for Clinical Excellence and its value judgments [PDF]

open access: yes, 2004
The National Institute for Clinical Excellence (NICE) offers health professionals in England and Wales advice on providing NHS patients with the highest attainable standards of care.
Culyer, A.J., Rawlins, M.D.
core   +2 more sources

Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm

open access: yesViruses, 2023
(1) Background: Some severe COVID-19 patients develop hyperinflammatory cytokine storm syndrome (CSS). We assessed the efficacy of anakinra added to standard of care (SoC) in hospitalized COVID-19 CSS patients.
Lesley E. Jackson   +6 more
doaj   +1 more source

Protective effect of anakinra on audiovestibular function in a murine model of endolymphatic hydrops

open access: yesFrontiers in Cellular Neuroscience, 2022
IntroductionMénière’s disease (MD), a common disease in the inner ear, is characterized by an increase in endolymph in the cochlear duct and vestibular labyrinth. The pathophysiology of the condition appears to be the immune response.
Na Zhang   +41 more
doaj   +1 more source

Candida albicans colonization and dissemination from the murine gastrointestinal tract : the influence of morphology and Th17 immunity [PDF]

open access: yes, 2014
This article is protected by copyright. All rights reserved. This work was supported by the Wellcome Trust (086558, 080088, 102705), a Wellcome Trust Strategic Award (097377) and a studentship from the University of Aberdeen. D.K.
Brown, Alistair J P   +9 more
core   +1 more source

Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study

open access: yesFrontiers in Pediatrics, 2023
BackgroundThe treatment of multisystem inflammatory syndrome in children unresponsive to first-line therapies (IVIG and/or steroids) is challenging. The effectiveness of IL-1 receptor antagonist, anakinra, is debated.Patients and methodsWe conducted an ...
Francesco Licciardi   +19 more
doaj   +1 more source

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

open access: yes, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet   +9 more
core   +1 more source

Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study

open access: yesCritical Care, 2020
Background A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases.
Emma J. Kooistra   +11 more
doaj   +1 more source

Reimann's "Habitual Hyperthermia" Responding to Hormone Therapy. [PDF]

open access: yes, 2016
A 25-year-old woman presented with fever of unknown origin, exhibiting malaise and low-grade fevers in evenings. These fevers exhibited a pattern of starting mid-menstrual cycle with resolution around the onset of menses, matching a pattern of "habitual ...
Currier, Judith S, Yang, Otto O
core   +2 more sources

Expedited Desensitization to Canakinumab

open access: yesAllergy & Rhinology, 2020
Introduction Interleukin-1 (IL-1) antagonists have been successful in the management of monogenic auto-inflammatory diseases, notably classic hereditary fever syndromes, such as Familial Mediterranean Fever (FMF). Anakinra (Kineret®), a human recombinant
Neha Sanan DO   +3 more
doaj   +1 more source

IL-1 Receptor Antagonist Anakinra Inhibits the Effect of IL-1β- Mediated Osteoclast Formation by Periodontal Ligament Fibroblasts

open access: yesBiology
Rheumatoid arthritis and periodontitis are comorbidities that share mutual pathways. IL-1β is a pro-inflammatory cytokine that plays a crucial role in both diseases.
Elizabeth Steemers   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy